Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Gastroenterology. 2015 Dec 8;150(4):918–930.e13. doi: 10.1053/j.gastro.2015.11.049

Figure 6. Immunohistochemistry of phospho-ERK1/2 in Selumetinib treated mouse stomachs.

Figure 6

Sections of the fundic glands from Mist1-Kras-mTmG mice treated at 3 months after tamoxifen treatment with DMSO, Selumetinib-treated, or 2 weeks post Selumetinib treatment and wild type mouse (control) were examined for phospho-ERK1/2 immunostaining. A) The stomachs from Mist1-Kras-mTmG mice treated with DMSO showed strong phospho-ERK1/2 staining throughout the metaplastic glands. The stomachs from Mist1-Kras-mTmG mice treated with Selumetinib (B) or at 2 weeks post Selumetinib treatment (C) showed decreases in phospho-ERK1/2 compared to the DMSO treated mice. D) In the control mouse stomachs, phosphorylation of ERK1/2 was occasionally observed in the foveolar or progenitor cells in the neck region. Boxes indicate regions enlarged. Scale bars = 100 μm. E) The phospho-ERK1/2 (+) cells were counted in all mucosal areas of corpus from DMSO- (n=5), Selumetinib-treated (n=4) or at 2 weeks post Selumetinib treatment (n=3) mice. *p< 0.05.